Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > March 1, 2023
Daily News
March 1, 2023
- Nichi-Iko Exits North American Market, Biosimilar Biz with Sagent Sell-Off
March 1, 2023
- AstraZeneca Files Anti-RSV Antibody Nirsevimab in Japan
March 1, 2023
- Nippon Chemiphar Out-Licenses XOR Inhibitor to Chinese Pharma
March 1, 2023
- UCB Japan Files Rozanolixizumab for Generalized Myasthenia Gravis
March 1, 2023
- Shelf Life of Ronapreve, Xevudy Extended to 30 Months in Japan
March 1, 2023
- Ono Seeks Japan Nod for Malignant Mesothelioma for Opdivo
March 1, 2023
- Actemra Filed in Japan for CRS Induced by Cancer Treatment: Chugai
March 1, 2023
- Lecanemab Earns Priority Review Status in China: Eisai
March 1, 2023
- Japan Approves Pfizer’s Omicron-Tailored Vaccine for Ages 5-11
March 1, 2023
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…